Huguet Pérez Jorge, Palou Joan, Millán Rodríguez Félix, Villavicencio Mavrich Humberto, Rodríguez José Vicente
Servicio de Urología, Fundación Puigvert, Barcelona, España.
Arch Esp Urol. 2002 Jan-Feb;55(1):50-6.
To analyze the indications and outcome of cystectomy for superficial bladder cancer since the introduction of BCG therapy.
From June 1990 to December 1996, 384 patients underwent cystectomy for transitional cell bladder tumor. A retrospective study was carried out on 43 cases (11.1%) that underwent cystectomy for Tis, Ta, T1 tumors. The characteristics of patients with superficial bladder cancer, correlation between the clinical stage (determined after TUR) and pathological findings (cystectomy specimen) and outcome were analyzed.
36 patients were male and 7 were female; mean age 63 years (range 39-79). Mean follow-up was 48 months (8-120). Twenty-nine patients received BCG therapy prior to surgery. No response to BCG was the main indication for cystectomy. By clinical stage, 79% were high grade, 65% T1 and 65% CIS. A correlation between the clinical stage and the pathological findings was found in 32.5%, overstaging in 28% and understaging in 39.5%. The increase in stage after analysis of the surgical specimen in 13 patients (30%) was due to progression of the superficial bladder tumor to infiltrating or metastatic tumor. Urinary tract tumor was found during follow-up in 8 patients (18.6%). Eleven patients died of bladder cancer, 3 of other causes and 29 (67%) are free of disease. Seven of the 13 patients (53%) that were clinically understaged and had infiltrating tumor or metastasis died.
No response to BCG therapy was the main indication for cystectomy. Before starting conservative treatment for high risk superficial bladder cancer, the possibility of endoscopic understaging should be taken into account. Patients undergoing cystectomy for superficial bladder cancer have a high risk of developing urinary tract tumor.
分析卡介苗(BCG)治疗引入后浅表性膀胱癌膀胱切除术的适应证及疗效。
1990年6月至1996年12月,384例患者因移行细胞膀胱肿瘤接受膀胱切除术。对43例(11.1%)因Tis、Ta、T1肿瘤接受膀胱切除术的患者进行回顾性研究。分析浅表性膀胱癌患者的特征、临床分期(经尿道膀胱肿瘤电切术[TUR]后确定)与病理结果(膀胱切除标本)之间的相关性及疗效。
36例男性,7例女性;平均年龄63岁(范围39 - 79岁)。平均随访48个月(8 - 120个月)。29例患者在手术前接受了卡介苗治疗。对卡介苗无反应是膀胱切除术的主要适应证。按临床分期,79%为高级别,65%为T1期,65%为原位癌(CIS)。临床分期与病理结果之间存在相关性的占32.5%,分期过高的占28%,分期过低的占39.5%。13例患者(30%)手术标本分析后分期增加是由于浅表性膀胱肿瘤进展为浸润性或转移性肿瘤。随访期间8例患者(18.6%)发现尿路肿瘤。11例患者死于膀胱癌,3例死于其他原因,29例(67%)无疾病。13例临床分期过低且有浸润性肿瘤或转移的患者中有7例(53%)死亡。
对卡介苗治疗无反应是膀胱切除术的主要适应证。在开始对高危浅表性膀胱癌进行保守治疗之前,应考虑内镜分期过低的可能性。接受浅表性膀胱癌膀胱切除术的患者发生尿路肿瘤的风险较高。